Doxorubicin Hydrochloride Injection, Powder, Lyophilized, For Solution
Product Images NDC 0143-9092
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Doxorubicin Hydrochloride (NDC 0143-9092). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fig. 1 (Doxorubicin HCl For Injection Usp 2)
Figure 1 shows a meta-analysis of disease-free survival. The hazard ratio for each trial is listed, as well as the 95% confidence interval. The trials include NSABP B-15, SEOSA, ONCOFRANCE, SE Sweden BCG A, NSABC Israel Bro283, and Austrian BCSG 3. The meta-analysis compares six studies that used Doxo with CMF (not identified). The graph shows that Doxo is better than CMF in some cases and worse in others. The text ends with a boundary for non-inferiority with CMF, which is retained at 75% of the CMF effect.*
Fig. 2 (Doxorubicin HCl For Injection Usp 3)
10 mg Vial (Doxorubicin HCl For Injection Usp 4)
This is a medication called DOXOrubicin HCI for injection, which is available only by prescription. Each vial contains 10mg of Doxorubicin HCI, USP and 50mg of Lactose Monohydrate, NF. The vial is single-dose and should be used for intravenous use only after reconstitution with 5mL of 0.9% Sadium Chioride Injection, USP. The usual dosage must be checked in the package insert. Unreconstituted vial should be stored at 20° to 25°C (68 10 77°F) [See USP] away from light and should be used before the expiration date. After reconstitution, any unused portion of the vial should be discarded. Severe complications like cellults, vesication and tissue necrosis can occur if the drug is extravasated during administration. The product is distributed by Hikma.*
50 mg Vial (Doxorubicin HCl For Injection Usp 5)
This is a prescription drug with the National Drug Code 0143-9093-01. It contains Doxorubicin HCI to be used intravenously after reconstitution with 25 mL 0.9% Sodium Chloride Injection USP. Each single-dose vial contains 50 mg of Doxorubicin HCI and 250 mg of Lactose Monohydrate, NF. The drug should be stored between 20° to 25°C till use while protecting it from light. The vial should be discarded if some portion of the drug is unused. Severe cellulitis, vesication, and fissure necrosis will occur if extravasation happens during administration. The manufacturer is THYMOORGAN PHARMAZIE GribH, Germany, and the drug is distributed by Hikina, Berkeley Heights, 07922.*
Representative Carton Serialization Image (Doxorubicin HCl For Injection Usp 6)
Representative Carton Serialization Image (Doxorubicin HCl For Injection Usp 7)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.